Methods and kits for cell activation
Provided herein are methods of activating immune cells. The method includes providing a population of immune cells and contacting the population of immune cells with a first agent and a second agent. The first agent includes an immune cell activator attached to a first binder moiety, and the second agent includes at least one capture oligomer. The at least one capture oligomer is capable of associating with the first binder moiety. Also provided are kits for activating immune cells.
1. A method of activating immune cells, the method comprising:
a) providing a population of immune cells; and
b) contacting the population of immune cells with a first agent and a second agent,
wherein the first agent comprises an immune cell activator attached to a first binder moiety,
wherein the second agent comprises at least one capture oligomer,
wherein the at least one capture oligomer is capable of associating with the first binder moiety, and
wherein the first binder moiety is a first binder nucleic acid sequence.
2. The method of claim 1 , wherein the immune cell activator is attached to the first binder nucleic acid sequence via a covalent linkage.
3. The method of claim 1 , wherein the immune cell activator is non-covalently attached to the first binder nucleic acid sequence via an intermediate binder moiety.
4. The method of claim 3 , wherein the intermediate binder moiety is selected from a group consisting of a secondary antibody, a biotin, an avidin, and a combination thereof.
5. The method of claim 3 , wherein the intermediate binder moiety is attached to the first binder nucleic acid sequence via a covalent linkage.
6. The method of claim 5 , wherein the intermediate binder moiety is capable of attaching with the immune cell activator via a non-covalent interaction.
7. The method of claim 1 , wherein the first agent is formed in situ in a medium containing the population of immune cells.
8. The method of claim 1 , wherein the second agent is a capture nucleic acid polymer comprising at least one capture oligonucleotide and wherein the at least one capture oligonucleotide is complementary to the first binder nucleic acid sequence.
9. The method of claim 1 , wherein the immune cell is a natural killer cell and the immune cell activator is a natural killer cell activator, wherein the natural killer cell activator is an anti-CD335 antibody, an anti-CD244 antibody, anti-CD2 antibody or combinations thereof.
10. A method of activating T cells, the method comprising:
a) adding to a population of T cells, an anti-CD3 antibody, a first binder moiety attached to a secondary antibody, and a second agent comprising at least one capture oligomer; and
b) incubating the population of T cells,
wherein the secondary antibody is capable of attaching with the anti-CD3 antibody,
wherein the at least one capture oligomer is capable of associating with the first binder moiety, and
wherein the first binder moiety is a first binder nucleic acid sequence.
11. The method of claim 10 , wherein the anti-CD3 antibody is attached to the first binder nucleic acid sequence via a covalent linkage.
12. The method of claim 10 , wherein the anti-CD3 antibody is non-covalently attached to the first binder nucleic acid sequence via an intermediate binder moiety.
13. The method of claim 10 , wherein the secondary antibody is non-covalently attached to the at least one capture oligomer via an intermediate binder moiety.
14. The method of claim 10 , wherein the at least one capture oligomer is complementary to the first binder nucleic acid sequence.